Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.50 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.50 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.50 |
| ▸ | CETP | P11597 | 1/20 | 0.50 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.50 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.49 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.49 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12435848 | 1.00 | FAAH (0.67) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL2216615 | 0.87 | MEN1 (0.69) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL2219567 | 0.87 | MEN1 (0.69) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL10168774 | 0.87 | MEN1 (0.65) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL12435716 | 0.87 | MEN1 (0.69) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL2219562 | 0.87 | MEN1 (0.69) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL7765651 | 0.87 | MEN1 (0.69) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL7769510 | 0.87 | MEN1 (0.69) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL12435711 | 0.87 | MEN1 (0.69) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL12435715 | 0.87 | MEN1 (0.69) | FAAHMEN1KMT2AMAPK1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW (IL) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | GPR119, FABP4, LIPC | FAAH 97/4885MEN1 4530/4885KMT2A 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.